Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Merit Medical Systems, Inc. (NASDAQ: MMSI) provide detailed information on the company’s financial condition, operations, risk factors, and material events as a Utah‑incorporated medical device and healthcare technology company. Through Forms 10‑K and 10‑Q, investors can review net sales by segment, gross profit, operating expenses, and other key metrics for Merit’s Cardiovascular and Endoscopy businesses, along with discussions of risks related to regulation, reimbursement, supply chain, acquisitions, and market conditions.
Merit also uses Form 8‑K to report significant developments. Recent 8‑K filings have furnished press releases on quarterly and preliminary revenue results, financial guidance, and non‑GAAP measures such as constant currency revenue, non‑GAAP operating margin, non‑GAAP net income, and non‑GAAP earnings per share. Other 8‑Ks disclose leadership and board changes, including the appointment of a new President and Chief Executive Officer and related compensation arrangements, as well as transitions in board roles.
Additional 8‑K filings document acquisition activity and product updates. Merit has reported signing and closing an asset purchase agreement to acquire the C2 CryoBalloon device and related technology, including the proposed purchase consideration and the expected impact on revenue and earnings measures. The company has also furnished press releases on updates to its WRAPSODY Cell‑Impermeable Endoprosthesis product, including commercialization and reimbursement developments.
On this page, Stock Titan presents Merit’s SEC filings with real‑time updates from EDGAR and AI‑powered summaries that explain the context and key points of each document. Investors can quickly scan annual reports (Form 10‑K), quarterly reports (Form 10‑Q), and current reports (Form 8‑K) to understand segment performance, non‑GAAP reconciliations, acquisition terms, leadership changes, and risk disclosures. Filings related to executive appointments and compensation, as well as transaction‑related disclosures, help users analyze governance and incentive structures alongside the company’s operating and financial trends.
The issuer filed a Form 144 indicating that a holder plans to sell 5,000 shares of common stock under Rule 144.
The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/06/2026 and an aggregate market value of $450,000. The filing notes that 59,290,248 shares of this class were outstanding.
The 5,000 shares were acquired on 01/06/2026 via a stock option exercise from the issuer, paid for in cash on the same date.
Merit Medical Systems (MMSI)10,000 shares of common stock at a weighted average price of
The insider also had indirect holdings of 8,280.258 shares through a spouse, 98,132 shares through a 401(k) plan as of
Merit Medical Systems (MMSI)11/21/2025, he sold 25,000 shares of common stock at a weighted average price of $87.31, with individual trades ranging from $87.0000 to $87.6708. After this sale, he directly owns 1,029,955 shares of Merit Medical common stock.
He also reports indirect ownership of 8,280.258 shares held by his spouse, 98,132 shares held in a 401(k) plan as of 10/31/2025, and 90 shares held by his spouse as custodian for a child, while expressly disclaiming beneficial ownership of the spouse’s securities. In addition, he holds non-qualified stock options to purchase 100,334 shares at $37.71 exercisable through 02/26/2027, 58,083 shares at $56.25 through 03/19/2028, and 54,302 shares at $70.58 through 02/28/2030, each vesting in 25% annual installments from their respective commencement dates.
Merit Medical Systems (MMSI) Executive Chairman and director reported an insider stock sale. On 11/20/2025, the reporting person sold 20,000 shares of Merit Medical common stock at a weighted average price of $85.1325 per share. The filing notes that these shares were sold in multiple transactions within a price range from $85.01 to $86.3499 per share.
After this sale, the reporting person directly owned 1,054,955 shares of common stock. In addition, there were indirect holdings of 8,280.258 shares through a spouse, 98,132 shares through a 401(k) plan as of 10/31/2025, and 90 shares held by a spouse as custodian for a child. The report also lists non-qualified stock options with exercise prices between $37.71 and $70.58 covering a total of 212,719 shares, with vesting in equal 25% annual installments beginning on their respective commencement dates.
Merit Medical Systems executive chairman and director reported selling 5,000 shares of common stock on 11/18/2025 at a weighted average price of $84.826 per share. Following this sale, he directly owns 1,074,955 shares, with additional indirect holdings including 8,280.258 shares held by his spouse, 98,132 shares in a 401(k) plan as of 10/31/2025, and 90 shares held by his spouse as custodian for a child.
He also holds non-qualified stock options to purchase 100,334 shares at $37.71 exercisable through 02/26/2027, 58,083 shares at $56.25 exercisable through 03/19/2028, and 54,302 shares at $70.58 exercisable through 02/28/2030, each becoming exercisable in 25% annual installments from their respective commencement dates. The filing notes the spouse’s holdings are disclaimed as beneficial ownership.
Merit Medical Systems furnished a Form 8-K to share a press release with updates on U.S. reimbursement and commercial strategies for its WRAPSODY® Cell-Impermeable Endoprosthesis. The press release is attached as Exhibit 99.1 and provides product-related commercial and reimbursement developments. The disclosure under Item 7.01 is furnished pursuant to General Instruction B.2 and is not deemed “filed” under the Exchange Act, nor incorporated by reference into other filings.
Merit Medical Systems (MMSI) closed the C2 CryoBalloon acquisition. The company reported that on November 3, 2025, it completed the purchase of the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The deal follows a definitive asset purchase agreement previously announced.
The disclosure is furnished under Item 7.01 (Regulation FD) and, along with Exhibit 99.1, is not deemed “filed” under the Exchange Act. The company also included a comprehensive safe harbor statement regarding forward-looking statements tied to integration, development, commercialization, and performance outcomes related to the C2 CryoBalloon assets.
Merit Medical Systems (MMSI) filed its Q3 2025 10‑Q, reporting higher sales and steady profitability. Net sales were $384,157,000, up from $339,845,000 a year ago. Gross profit reached $186,411,000 versus $157,535,000. Income from operations was $42,612,000 compared with $37,261,000. Net income was $27,755,000, slightly below $28,444,000 last year. Diluted EPS was $0.46 versus $0.48.
Year to date, net sales were $1,121,970,000 vs. $1,001,356,000, and operating cash flow rose to $198,861,000 from $152,055,000. Cardiovascular segment sales were $366,425,000 in the quarter (from $322,855,000), and Endoscopy was $17,732,000 (from $16,990,000).
Cash and cash equivalents were $392,457,000, with long‑term debt of $732,916,000 related to 3.00% Convertible Notes due 2029. The company had approximately $697,000,000 in additional available borrowings under its revolver. MMSI closed the Biolife acquisition for an upfront $120,000,000 plus $7,200,000 adjustments; Biolife products contributed about $6,600,000 in net sales since closing. The effective tax rate increased to 28.0% for the quarter, reflecting legislation enacted during the period. Shares outstanding were 59,290,248 as of October 28, 2025.
Merit Medical Systems, Inc. filed a Form 8-K after issuing a press release with its operating and financial results for the quarter ended September 30, 2025. The company also held a conference call with a live webcast and slide presentation to discuss these third-quarter results and its outlook.
The press release, titled “Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance,” and the conference call slides are provided as Exhibits 99.1 and 99.2. Merit highlights both GAAP and non-GAAP financial measures and states that detailed reconciliations to comparable GAAP figures are included in these materials. The company explains that it does not provide full GAAP guidance for certain metrics because it cannot reasonably predict the impact of acquisition-related items, non-cash amortization, severance, litigation, and regulatory changes on future results.
Merit Medical Systems (MMSI) announced a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The total purchase consideration is $22 million, including $19 million cash at closing and up to $3 million in contingent payments tied to milestones.
The closing is expected in Q4 2025, subject to satisfaction or waiver of customary closing conditions. Merit referenced non-GAAP measures in its press release and stated that a quantitative reconciliation to GAAP is not available without unreasonable effort.